
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

April 2, 2014
Date of Report (date of earliest event reported)

TransEnterix, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

0-19437
(Commission
File Number)

11-2962080
(I.R.S. Employer
Identification Number)

635 Davis Drive, Suite 300
Morrisville, North Carolina
(Address of principal executive offices)

919-765-8400
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

TransEnterix, Inc. (the "Company") updated its Company presentation (the "Presentation") on April 2, 2014. A copy of the Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Presentation will be used during investor meetings beginning on April 2, 2014.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	TransEnterix, Inc. Company presentation dated April 2, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 2, 2014

TRANSENERIX, INC.

/s/ Joseph P. Slattery

Joseph P. Slattery
Executive Vice President and Chief
Financial Officer



Todd M. Pope, President & CEO
Joe Slattery, EVP & CFO

April 2, 2014

Cautionary Statement



Any statements contained in this presentation that do not describe historical facts, including statements about the beliefs and expectations of TransEnterix, Inc. ("TransEnterix," "we" or "our"), may constitute forward-looking statements as that term is defined by the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expect," "anticipate," "future," "intend," "plan," "believe," "estimate," "confident" and similar statements. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations.

Potential risks and uncertainties include the risks outlined in this presentation and TransEnterix' filings with the U.S. Securities and Exchange Commission, including the benefits and opportunities of surgical robotics, whether the combined company formed as a result of the Sept. 2013 merger of TransEnterix and SafeStitch Medical, Inc. will be successful in 2014 and beyond, the success and market opportunity of our continuing and new product development efforts, including the SurgiBot system, the pace of adoption of our product technology by surgeons, the effect on our business of existing and new regulatory requirements, the outcome of coverage and reimbursement decisions by the government and third party payors, and other economic and competitive factors. We caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



*Advancing Surgery
Through Innovation*

Issuer:	TransEnterix, Inc.
Ticker (Exchange):	TRXC (NYSE MKT) ⁽¹⁾
Amount Offered:	\$50 million
Over-Allotment Option:	15%
Lock-up Provision:	90 days
Expected Pricing:	April 10, 2014
Bookrunners:	Stifel / RBC Capital Markets
Use of Proceeds:	For research and development, sales and marketing, and commercialization related to our SurgiBot™ System, working capital and other general corporate purposes.

⁽¹⁾ Authorized for listing upon completion of offering. Currently listed as "TRXCD" on OTC:BB

Focus

- Surgical robotics

Technology

- Developing patient-side robotic platform: SurgiBot

Solution

- Addresses unmet needs in today's robotic offerings
 - Cost effective
 - Broad procedure applicability


Market

- Large addressable market – ~2M US procedures

Experience

- Strong management team

The SurgiBot System is currently under development





Open
Surgery



Rigid
Laparoscopy
(1989)




Flexible
Laparoscopy
(2010)

Spider Surgical System

Enabling Flexible Laparoscopy




- Internal (intra-abdominal) triangulation
- Flexible, articulating instruments for dissection and retraction
- True left/right instrumentation
- Lower profile port of access
- Over 3,500 procedures performed
- Broad procedural mix


A large, faint, light blue version of the TransEnterix logo is visible in the background of the central text area.

SurgiBot™
*Powered and Robotically-enabled
Next-generation Platform**

**The SurgiBot System is currently under development*



Worldwide daVinci Procedures



Source: ISRG Investor Presentation, 2/21/2014

	Multi-Port	<i>SurgiBot</i>
Surgeon scrubbed-in	✗	✓
Multi-quadrant utility	✗	✓
Reduced incisions	✗ ⁽¹⁾	✓
Internal triangulation	✗	✓
Articulating instruments	✓ ⁽¹⁾	✓
Space for assistant	✗	✓
Cost	~\$1.5M ⁽²⁾	~\$500K

(1) “Single-site” upgrade reduces incisions, with added cost and loss of articulating instruments

⁽²⁾ ISRG investor call, 1/23/2014

SurgiBot

First Patient-side Robotic Platform



Surgeon scrubbed-in

Easily repositioned for multi-quadrant surgery

Flexible, articulating channels & instruments

Steerable 3DHD

Small, mobile platform

Cost effective platform



The SurgiBot System is currently under development

SurgiBot

First Patient-side Robotic Platform



SurgiBot




**3DHD
Optics/Cart**

The SurgiBot System is currently under development


[Video of SurgiBot System Prototype]

The SurgiBot System is currently under development



Source: Millennium Research Group US Markets Laparoscopic Devices 2014

Over 5,000 Hospitals in the United States



Hospitals without Robotic Capability

- Current robotic offerings are not cost effective
 - System price
 - Limited procedure volume
- Surgery centers – untapped market for robotics
- Losing market share to robotic facilities
- Large underpenetrated OUS opportunity

Hospitals with Robotic Capability

- Invested in the strategic and competitive value of robotic surgery
- ROI expectations changing/under pressure
- Potential for diversification of robotic solutions
 - Procedures
 - Price
 - Facilities


Mid/Small Hospitals

- >3,000 w/ <300 beds
- >80% lack robotic offering
- Losing market share to robotic facilities
- Represent >800K target annual procedures

Surgery Centers

- ~5,000 in US
- Economics driving rapid procedure growth
- SurgiBot will offer versatility and cost benefits

Combining Advanced Technology AND Maximizing Value



Highlights – Instrumentation

	Instrumentation Needs By Procedure			Status	
	Chole	Bariatrics	GYN	SPIDER	SurgiBot
Grasper	✓	✓	✓	Launched	Developed
Dissector	✓	✓	✓	Launched	Developed
Hook	✓	✓	✓	Launched	Developed
Clip Applier	✓			Launched	Developed
Shears	✓	✓	✓	Launched	Developed
Suction Irrigator	✓	✓	✓	Launched	Developed
Needle Driver		✓	✓	Launched	Developed
Advanced Energy		✓	✓	Q2 2014	Development
Bipolar Energy			✓	3 rd Party	Development
Stapler		✓		3 rd Party	3 rd Party



The SurgiBot System is currently under development

Operating Capabilities & Talent



R&D Team



Broad Experience



Rapid Prototyping



cGMP Manufacturing

Prior Experience

<p>Todd M. Pope <i>President and Chief Executive Officer</i></p>		
<p>Joe Slattery <i>EVP and Chief Financial Officer</i></p>		
<p>Richard Mueller <i>Chief Operating Officer</i></p>		
<p>Mohan Nathan <i>Vice President of Global Marketing</i></p>		
<p>Tammy Carrea <i>Vice President, Quality and Regulatory Affairs</i></p>		
<p>Nicole Bell <i>Vice President, Research and Development</i></p>		
<p>Larry Pope <i>Vice President, Operations</i></p>		

Board of Directors

- **Paul LaViolette**
 - Chairman of TransEnterix
 - Partner, SV Life Sciences
- **Todd Pope**
 - President and Chief Executive Officer, TransEnterix
- **Dennis Dougherty**
 - Founder, Intersouth Partners
- **David Milne**
 - Managing Partner, SV Life Sciences
- **William Starling**
 - Managing Director, Synergy Life Science Partners
- **Phillip Frost, M.D.**
 - CEO and Chairman of OPKO Health
 - Chairman of Teva Pharmaceuticals
- **Jane Hsiao, Ph.D., MBA**
 - Former Chairman of SafeStitch
 - Vice Chairman and CTO of OPKO Health
- **Aftab Kherani, M.D.**
 - Principal of Aisling Capital
- **Richard Pfenniger, Jr.**
 - Former Chairman/CEO of Continucare
 - Former CEO of Whitman Education Group

Healthcare Investors



2013

- Design & Pre-clinical Testing
- Pre-submission FDA Meeting

2014

- First Human Procedures
- Regulatory Submissions

2015

- Regulatory Clearances
- Global Launch

- 510(k) pathway
- General intended use for laparoscopic abdominal access



***Financial
Information***

Recurring Revenue Model

US Pricing:

- Capital sale ~\$500K
- Instruments ~\$1,000-1,500/procedure
- Service ~\$50K/year

International:

- Market-specific pricing
- Distributors provide service/support



The SurgiBot System is currently under development

- Cash
 - Balance at 12/31/2013 \$16.2M
 - Q4 '13 burn \$8.7M, incl. \$0.9M debt service and \$0.7M capital equipment
- Capital Sales Reps
 - Hire 5-8 early 2015
 - ~15 by launch
 - ~30 to cover US
 - Supported by clinical and field service reps
- Gross Margin
 - SurgiBot system $\geq 50\%$
 - Instruments scaling to $>60\%$
 - Service break-even requires scale

- FDA Pre-filing Submission - Q1 *Completed*
- Launch Flexible Advanced Energy Device - Q2
- Clinical SurgiBot Cases Begin - Q3
- SurgiBot FDA/CE Filings - Q4

Focus

- Surgical robotics

Technology

- Developing patient-side robotic platform: SurgiBot

Solution

- Addresses unmet needs in today's robotic offerings
 - Cost effective
 - Broad procedure applicability

Market

- Large addressable market – ~2M US procedures

Experience

- Strong management team

The SurgiBot System is currently under development